ResMed enters the back half of June with a fresh downgrade from a bellwether bank landing just as short sellers are pulling back — a split signal that makes the stock's next move harder to read than usual.
The analyst story dominated the week. Morgan Stanley's David Bailey moved RMD to Equal-Weight from Overweight Tuesday, cutting his price target to $230 from $286 — a 20% reduction that reflects genuine recalibration, not a trim. It followed Citigroup lowering its target to $270 from $340 Monday, while keeping a Buy rating. Both moves point in the same direction: the Street still broadly likes the business, but is cutting what it's willing to pay for it. The consensus sits at Hold, with a mean target near $262 — roughly 35% above the current price of $193.94. That gap is large enough to suggest either a mis-priced stock or a Street that is catching up to a deteriorating growth story and hasn't finished trimming targets. Given two material cuts in two days, the latter looks more plausible. RBC Capital is the outlier, raising its target to $321 in May and maintaining Outperform — but that call is now more than six weeks old and pre-dates this week's pressure.
The positioning picture is less alarming than the analyst headlines suggest. Short interest has fallen sharply — down 10.7% on the week to 8.5% of the free float, reversing a spike that briefly pushed borrowed shares above 13.8 million in early June. That unwind matters: shorts appear to have pressed the position hard into early June and are now reducing, not adding. Borrow conditions confirm there is no urgency on either side. Cost to borrow is just 0.52%, down roughly 16% on the week, and availability is a comfortable 269% — meaning nearly three shares remain available to lend for every one already borrowed, well within normal range and near the upper end of the past year's band. Options positioning adds a different texture: the put/call ratio is running at 1.92, just fractionally below its 20-day average of 1.92, and the z-score is essentially flat. That level is structurally elevated — it has been running well above 1.0 since late May, up from the 1.0–1.2 range seen in early May — but it is no longer moving. Options traders are cautious, but they were already cautious. The short score of 65.5 is consistent with moderate-to-elevated short pressure and has edged lower from 67.4 a week ago.
The bull and bear cases for RMD are well-defined and genuinely unresolved. Bulls point to 62.3% gross margins beating consensus by 40 basis points, mask sales growing 16% year-over-year, and an EPS of $2.81 that cleared estimates — a track record reflected in the EPS surprise factor score of 60. The business scores in the 69th percentile on EV/EBIT, suggesting reasonable value relative to the broader universe, and the PE ratio has compressed to roughly 16.8x on a trailing basis, down about 1x over the past 30 days. Bears focus on management guiding FY26 growth lower — mid-single-digit rather than high-single-digit — international device sales underperforming, and the persistent GLP-1 overhang. The EPS forward 12-month growth factor ranks in only the 23rd percentile, suggesting the Street's forward estimates are soft. Morgan Stanley's cut is essentially a vote for the bear case on near-term catalysts, and the valuation, while compressed, has not yet found a floor that attracts buyers at scale.
CEO Mick Farrell has sold approximately 5,000 shares in each of the past three months — June 8, May 7, and April 7 — at progressively lower prices ($193.96, $207.82, and $225.50 respectively). The CFO and founder also sold in April. These appear to be scheduled disposals rather than opportunistic selling, given the regular cadence and consistent share count. The significance scores are low (rated 2 out of 10 by ORTEX). But the direction of travel is worth noting: insiders are consistently reducing at prices well above today's close.
The next scheduled earnings date is July 30. RMD fell 3.3% on the day after its most recent print on April 30, and dropped a further 2.4% over the following five days. With two analyst target cuts in the same week and shorts retreating rather than pressing, the setup into that print is one where the positioning is less charged than the headline analyst noise implies — but where the burden of proof on the growth story is clearly rising.
See the live data behind this article on ORTEX.
Open RMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
